ALPX S-1/Aamended IPO prospectus

Executive Summary

Alopexx develops vaccines and antibodies for infection prevention in older adults and hospital patients, aiming to earn money from product sales and licensing but currently generating no revenue. Its lead programs target PNAG, a microbial surface molecule, to provide broader protection than treatments directed at individual pathogens or serotypes. Development remains early, and H1 2026 net loss was $(1.01)M despite constrained spending. The unpriced, all-primary IPO would raise $30–$36M gross at an implied $83.0–$99.6M market capitalization, giving offering buyers 36% of outstanding shares. Buyers are funding proof-of-concept studies—not a fully financed path to approval—and need laboratory findings to translate into clinical protection.

Business Model and Growth Drivers

Alopexx’s two leading candidates offer different forms of protection. AV0328 is a synthetic vaccine intended to stimulate patients’ antibodies and complement existing pneumococcal vaccines. Its completed Phase 1 trial enrolled 16 healthy volunteers, reported no serious adverse events, and produced antibodies with laboratory killing activity across tested PNAG-positive organisms; clinical protection remains unproven. F598 supplies antibodies directly through an infusion, potentially providing immediate protection for two to three months alongside antibiotics and antifungals. Phase 1 enrolled 20 healthy adults with no serious adverse events. A separate 25-person tuberculosis study did not meet its efficacy endpoint and could not establish bactericidal activity.

• Clinical priorities: AV0328’s proposed next study would assess dose, schedule and durability in ≈100 adults over 50. F598’s planned 1,600-patient study across eight Assistance Publique–Hôpitaux de Paris hospitals is anticipated to begin in Q1 2027 and finish ≈18 months later.
• Commercial model: Alopexx positions AV0328 as complementary to established vaccines, not a proven replacement. Management’s multibillion-dollar sales projections require successful trials, approval, reimbursement and substantial adoption.
• Partnerships and supply: Bharat Biopharm supports AV0328 development in licensed lower-income territories; a $0.667M upfront payment remains deferred rather than recognized revenue. Alopexx has no internal manufacturing and depends on suppliers including Glycosyn and Lonza.
• Expansion: Alzheimer’s and neuroinflammation candidates AV0407 and AB0411 are planned for development beginning Q1 2027, based on animal findings rather than demonstrated human benefit.

The Offering

• Size and implied valuation: 3,000,000 primary shares at an unpriced $10.00–$12.00 range imply $30–$36M gross proceeds and $83.0–$99.6M market capitalization on 8,299,557 post-offering shares; buyers receive 36%. Including 1,419,388 outstanding options and 150,000 representative warrants gives 9,868,945 fully diluted shares, $98.7–$118M capitalization and a 30% buyer stake, before future grants. Revenue and earnings multiples are not meaningful.
• Distribution: ThinkEquity represents the underwriters; its 45-day option covers another 450,000 shares. Listing approval for NYSE American under ALPX is required to complete the offering.
• Proceeds: At the assumed $11.00 price, estimated net proceeds are ≈$30.1M, or ≈$34.7M with the option. The company receives the money: ≈$6.0M for AV0328, ≈$9.0M for the antibody’s intensive-care trial, ≈$4.0M for neuroinflammation programs, and the remainder for general purposes.
• Asset backing: Each $11.00 share would be backed by $2.95 of net tangible assets after the IPO, an $8.05 gap. Existing holders paid an average $1.36 per share.
• Share supply: Directors, executives and the company face 365-day lock-ups; other holders generally face 180 days, subject to exceptions or waivers. Another 1,803,562 shares are reserved for future equity-plan issuance.

Key Financial Highlights

Dollar amounts in $M. “After IPO” assumes note conversion and 3,000,000 shares sold at $11.00, after offering costs; operating results remain historical.

• Capitalization bridge: The $17.7M accumulated deficit explains negative pre-IPO equity. Converting $1.25M principal plus $0.362M accrued interest into 195,425 shares improves equity to $(4.81)M; the offering then makes it positive. Deferred offering costs are charged against equity upon completion.
• Cash versus loss: Noncash stock-based compensation and unpaid expenses reduce immediate cash use relative to reported losses. Planned trials will make historical cash burn a poor guide to future spending.
• Runway: Management expects proceeds and existing cash to fund at least 12 months, but not a pivotal trial. A further $0.350M related-party borrowing was received after H1 2026.

Governance and Control

• Control: Common shares carry one vote each. CEO and co-founder Daniel Vlock’s expected 55.8% voting control includes qualifying options and note conversion; public buyers cannot determine corporate decisions.
• Oversight: Alopexx qualifies as a controlled company but does not currently intend to use governance exemptions. Its classified board and restrictions on shareholder actions strengthen incumbent control.
• Insider financing and compensation: Related parties supplied most borrowing, with interest rates of 8%–15% and repeated extensions. Vlock’s $0.525M annual salary becomes payable after the IPO, increasing the post-offering cost base.

Risk Assessment

• Going concern and controls: The auditor flags substantial doubt about continued operations; previously identified accounting-staffing and segregation weaknesses require effective remediation.
• Clinical and regulatory proof: Neither candidate has established infection-prevention efficacy, and regulators may reject AV0328’s proposed laboratory surrogate endpoint, requiring larger trials.
• Funding and valuation: The offering does not finance pivotal development, so buyers accept an $83.0–$99.6M valuation before clinical protection is proven and likely further dilution.
• Manufacturing dependence: Sole-source components and outsourced production expose trials to shortages, quality failures and costly supplier transfers.
• Intellectual property and adoption: Licensed rights carry payment and development obligations, while established vaccine competitors and reimbursement decisions could limit eventual returns.
• Concentrated control: Vlock’s majority voting position limits minority influence over financing, compensation and strategic decisions.

What to Watch

• AV0328: Watch whether the proposed older-adult study starts and produces durable antibody responses, and whether regulators accept the surrogate approach or require field-efficacy evidence.
• F598: Watch the company’s Q1 2027 trial-start plan and subsequent infection-related outcomes; recruitment delays or inconclusive results would weaken the intensive-care opportunity.
• Funding execution: Watch whether proceeds advance these trials before another financing is needed; management promises only at least 12 months of runway, not funding through approval.